{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:40:55Z","timestamp":1790671255879,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) infection often develop into cirrhosis, and both are major risk factors of hepatocellular carcinoma. However, effective approaches for the monitoring of HBV-related disease progress are still in need. Increased iron storage has an important role in HBV-related diseases. Hepcidin is a key regulator of iron homeostasis whose expression changes are often indicative of abnormal iron metabolism. There are few reports of hepcidin levels in patients with HBV infections, and the available results are inconsistent. In this study, using a recently validated nanopore silica film based method, we measured serum hepcidin levels in 46 HBV-related patients and 20 healthy controls. Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrhosis; and HBV-related cirrhosis with hepatocellular carcinoma. Compared to healthy controls, the mean serum hepcidin level was significantly higher in CHB patients without cirrhosis, and in those with hepatocellular carcinoma, but not in those with cirrhosis. Iron-loading, viral infection and liver dysfunction are determined to be the major regulators of hepcidin in these patients. These observations suggest correlations between serum hepcidin and progression of chronic HBV infection, and may shed a new light on the development of biomarkers for HBV-related disease surveillance.<\/jats:p>","DOI":"10.1038\/srep34252","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T09:33:52Z","timestamp":1475487232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay"],"prefix":"10.1038","volume":"6","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"BFsrep34252_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","volume":"23","author":"CJ Chu","year":"2008","unstructured":"Chu, C. J. & Lee, S. D. Hepatitis B virus\/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 23, 512\u2013520, (2008).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFsrep34252_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.idc.2009.01.005","volume":"23","author":"LL Gluud","year":"2009","unstructured":"Gluud, L. L. & Gluud, C. Meta-analyses on viral hepatitis. Infect. Dis. Clin. North. Am. 23, 315\u2013330, (2009).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"BFsrep34252_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrmicro1930","volume":"6","author":"H Drakesmith","year":"2008","unstructured":"Drakesmith, H. & Prentice, A. Viral infection and iron metabolism. Nat. Rev. Microbiol. 6, 541\u2013552, (2008).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep34252_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix, J. & Sherman, M. Management of hepatocellular carcinoma. Hepatology 42, 1208\u20131236, (2005).","journal-title":"Hepatology"},{"key":"BFsrep34252_CR5","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/hep.26130","volume":"57","author":"X Wang","year":"2013","unstructured":"Wang, X., Zhang, A. & Sun, H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 57, 2072\u20132077, (2013).","journal-title":"Hepatology"},{"key":"BFsrep34252_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/0016-5085(92)90339-Z","volume":"102","author":"A Di Bisceglie","year":"1992","unstructured":"Di Bisceglie, A., Axiotis, C., Hoofnagle, J. & Bacon, B. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 102, 2108\u20132113, (1992).","journal-title":"Gastroenterology"},{"key":"BFsrep34252_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","volume":"117","author":"MW Hentze","year":"2004","unstructured":"Hentze, M. W., Muckenthaler, M. U. & Andrews, N. C. Balancing acts: Molecular control of mammalian iron metabolism. Cell 117, 285\u2013297, (2004).","journal-title":"Cell"},{"key":"BFsrep34252_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","volume":"102","author":"THepcidin Ganz","year":"2003","unstructured":"Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102, 783, (2003).","journal-title":"Blood"},{"key":"BFsrep34252_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/bcmd.2002.0573","volume":"29","author":"G Nicolas","year":"2002","unstructured":"Nicolas, G. et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis. 29, 327\u2013335, (2002).","journal-title":"Blood Cells Mol. Dis."},{"key":"BFsrep34252_CR10","doi-asserted-by":"publisher","first-page":"G199","DOI":"10.1152\/ajpgi.00412.2005","volume":"290","author":"T Ganz","year":"2006","unstructured":"Ganz, T. & Nemeth, E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G199\u2013G203, (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"BFsrep34252_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-med-050109-142444","volume":"62","author":"T Ganz","year":"2011","unstructured":"Ganz, T. & Nemeth, E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62, 347\u2013360, (2011).","journal-title":"Annu. Rev. Med."},{"key":"BFsrep34252_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1039\/C4MT00063C","volume":"6","author":"T Konz","year":"2014","unstructured":"Konz, T., Montes-Bay\u00f3n, M. & Vaulont, S. Hepcidin quantification: methods and utility in diagnosis. Metallomics 6, 1583\u20131590, (2014).","journal-title":"Metallomics"},{"key":"BFsrep34252_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1373\/clinchem.2010.149187","volume":"56","author":"JJC Kroot","year":"2010","unstructured":"Kroot, J. J. C. et al. Immunochemical and Mass-Spectrometry\u2013Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clin. Chem. 56, 1570\u20131579, (2010).","journal-title":"Clin. Chem."},{"key":"BFsrep34252_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.nano.2014.02.005","volume":"10","author":"J Fan","year":"2014","unstructured":"Fan, J. et al. Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids. Nanomed. Nanotechnol. 10, 879\u2013888, (2014).","journal-title":"Nanomed. Nanotechnol."},{"key":"BFsrep34252_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.nano.2015.01.008","volume":"11","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Hepcidin levels in hyperprolactinemic women monitored by nanopore thin film based assay: Correlation with pregnancy-associated hormone prolactin. Nanomed. Nanotechnol. 11, 871\u2013878, (2015).","journal-title":"Nanomed. Nanotechnol."},{"key":"BFsrep34252_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.hepres.2006.08.006","volume":"36","author":"M Nagashima","year":"2006","unstructured":"Nagashima, M. et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol. Res. 36, 288\u2013293, (2006).","journal-title":"Hepatol. Res."},{"key":"BFsrep34252_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MEG.0b013e3283344708","volume":"22","author":"OF Olmez","year":"2010","unstructured":"Olmez, O. F., Gurel, S. & Yilmaz, Y. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. Eur. J. Gastroenterol. Hepatol. 22, 461\u2013465, (2010).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFsrep34252_CR18","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1007\/s10620-010-1183-8","volume":"55","author":"O Yonal","year":"2010","unstructured":"Yonal, O. et al. Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels. Dig. Dis. Sci. 55, 3548\u20133551, (2010).","journal-title":"Dig. Dis. Sci."},{"key":"BFsrep34252_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3748\/wjg.v16.i14.1747","volume":"16","author":"J Jaroszewicz","year":"2010","unstructured":"Jaroszewicz, J., Rogalska, M., Flisiak, I. & Flisiak, R. Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. World J. Gastroenterol. 16, 1747\u20131752, (2010).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep34252_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3945\/ajcn.2008.27232","volume":"89","author":"DM Frazer","year":"2009","unstructured":"Frazer, D. M. & Anderson, G. J. Hepcidin compared with prohepcidin: an absorbing story. Am. J. Clin. Nutr. 89, 475\u2013476, (2009).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFsrep34252_CR21","doi-asserted-by":"publisher","first-page":"e65551","DOI":"10.1371\/journal.pone.0065551","volume":"8","author":"D Lin","year":"2013","unstructured":"Lin, D. et al. Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis. PLoS One 8, e65551, (2013).","journal-title":"PLoS One"},{"key":"BFsrep34252_CR22","first-page":"1037","volume":"92","author":"X Wang","year":"2013","unstructured":"Wang, X., Cheng, P.-P., Jiang, F. & Jiao, X.-Y. The effect of hepatitis B virus infection on hepcidin expression in hepatitis B patients. Ann. Clin. Lab. Sci. 92, 1037\u20131042, (2013).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"BFsrep34252_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2893.2008.00972.x","volume":"15","author":"N Fujita","year":"2008","unstructured":"Fujita, N. et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J. Viral Hepat. 15, 498\u2013507, (2008).","journal-title":"J. Viral Hepat."},{"key":"BFsrep34252_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/13547500802033391","volume":"13","author":"J Jaroszewicz","year":"2008","unstructured":"Jaroszewicz, J., Rogalska, M. & Flisiak, R. Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis. Biomarkers 13, 478\u2013485, (2008).","journal-title":"Biomarkers"},{"key":"BFsrep34252_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2008.05.014","volume":"49","author":"N Fujita","year":"2008","unstructured":"Fujita, N. et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J. Hepatol. 49, 702\u2013710, (2008).","journal-title":"J. Hepatol."},{"key":"BFsrep34252_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1017\/S0007114507336829","volume":"97","author":"MA Roe","year":"2007","unstructured":"Roe, M. A. et al. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br. J. Nutr. 97, 544\u2013549, (2007).","journal-title":"Br. J. Nutr."},{"key":"BFsrep34252_CR27","doi-asserted-by":"crossref","unstructured":"Geerts, I., Vermeersch, P. & Joosten, E. Evaluation of the first commercial hepcidin ELISA for the differential diagnosis of anemia of chronic disease and iron deficiency anemia in hospitalized geriatric patients. ISRN Hematol. 567491, (2012).","DOI":"10.5402\/2012\/567491"},{"key":"BFsrep34252_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","volume":"142","author":"MW Hentze","year":"2010","unstructured":"Hentze, M. W., Muckenthaler, M. U., Galy, B. & Camaschella, C. Two to tango: regulation of mammalian iron metabolism. Cell 142, 24\u201338, (2010).","journal-title":"Cell"},{"key":"BFsrep34252_CR29","first-page":"71","volume":"39","author":"CA Aoki","year":"2005","unstructured":"Aoki, C. A. et al. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J. Clin. Gastroenterol. 39, 71\u201374, (2005).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFsrep34252_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2369-13-56","volume":"13","author":"Y Caliskan","year":"2012","unstructured":"Caliskan, Y. et al. Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. BMC Nephrol. 13, 56\u201356, (2012).","journal-title":"BMC Nephrol."},{"key":"BFsrep34252_CR31","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/j.1468-3083.2012.04511.x","volume":"27","author":"E Darwich","year":"2013","unstructured":"Darwich, E. et al. Increased serum hepcidin levels in patients with porphyria cutanea tarda. J. Eur. Acad. Dermatol. Venereol. 27, e68\u2013e74, (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFsrep34252_CR32","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1074\/jbc.M008923200","volume":"276","author":"C Pigeon","year":"2001","unstructured":"Pigeon, C. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276, 7811\u20137819, (2001).","journal-title":"J. Biol. Chem."},{"key":"BFsrep34252_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.gastro.2006.10.018","volume":"132","author":"A Pietrangelo","year":"2007","unstructured":"Pietrangelo, A. et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo . Gastroenterology 132, 294\u2013300, (2007).","journal-title":"Gastroenterology"},{"key":"BFsrep34252_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3748\/wjg.v5.i1.38","volume":"5","author":"J Wang","year":"1999","unstructured":"Wang, J., Wang, X. & Liu, P. Detection of serum TNF-alpha, IFN-beta, IL-6 and IL-8 in patients with hepatitis B. World J. Gastroenterol. 5, 38\u201340, (1999).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep34252_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1224577","volume":"338","author":"H Drakesmith","year":"2012","unstructured":"Drakesmith, H. & Prentice, A. M. Hepcidin and the iron-infection axis. Science 338, 768\u2013772, (2012).","journal-title":"Science"},{"key":"BFsrep34252_CR36","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2011-04-351957","volume":"118","author":"AE Armitage","year":"2011","unstructured":"Armitage, A. E. et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 118, 4129\u20134139, (2011).","journal-title":"Blood"},{"key":"BFsrep34252_CR37","first-page":"201","volume":"111","author":"H Ohzato","year":"1992","unstructured":"Ohzato, H. et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 111, 201\u2013209 (1992).","journal-title":"Surgery"},{"key":"BFsrep34252_CR38","doi-asserted-by":"publisher","first-page":"e39276","DOI":"10.1371\/journal.pone.0039276","volume":"7","author":"SO Park","year":"2012","unstructured":"Park, S. O., Kumar, M. & Gupta, S. TGF-beta and iron differently alter HBV replication in human hepatocytes through TGF-beta\/BMP signaling and cellular microRNA expression. PLoS One 7, e39276, (2012).","journal-title":"PLoS One"},{"key":"BFsrep34252_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0168-8278(00)00012-X","volume":"34","author":"P Chouteau","year":"2001","unstructured":"Chouteau, P. et al. Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2. 2.15 cells. J. Hepatol. 34, 108\u2013113, (2001).","journal-title":"J. Hepatol."},{"key":"BFsrep34252_CR40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jhep.2009.06.027","volume":"51","author":"D Girelli","year":"2009","unstructured":"Girelli, D. et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J. Hepatol. 51, 845\u2013852, (2009).","journal-title":"J. Hepatol."},{"key":"BFsrep34252_CR41","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1365-2893.2009.01244.x","volume":"17","author":"E Tsochatzis","year":"2010","unstructured":"Tsochatzis, E. et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J. Viral Hepat. 17, 800\u2013806, (2010).","journal-title":"J. Viral Hepat."},{"key":"BFsrep34252_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.0954-6820.1967.tb11502.x","volume":"182","author":"E Hasch","year":"1967","unstructured":"Hasch, E., Jarnum, S. & Tygstrup, N. Albumin synthesis rate as a measure of liver function in patients with cirrhosis. Acta Med. Scand. 182, 83\u201392 (1967).","journal-title":"Acta Med. Scand."},{"key":"BFsrep34252_CR43","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/S0168-8278(09)60232-4","volume":"50","author":"E Tsochatzis","year":"2009","unstructured":"Tsochatzis, E., Papatheodoridis, G., Koliaraki, V., Mamalaki, A. & Archimandritis, A. Serum hepcidin levels depend on aetiology but not severity of cirrhosis. J. Hepatol. 50, S93, (2009).","journal-title":"J. Hepatol."},{"key":"BFsrep34252_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1471-2407-8-167","volume":"8","author":"H Kijima","year":"2008","unstructured":"Kijima, H., Sawada, T., Tomosugi, N. & Kubota, K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 8, 167, (2008).","journal-title":"BMC Cancer"},{"key":"BFsrep34252_CR45","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00432-009-0585-5","volume":"135","author":"H-H Tseng","year":"2009","unstructured":"Tseng, H.-H. et al. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 135, 1413\u20131420, (2009).","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFsrep34252_CR46","doi-asserted-by":"crossref","unstructured":"Kessler, S. M., Laggai, S., Kiemer, A. K., Barghash, A. & Helms, V. Hepatic hepcidin expression is decreased in cirrhosis and HCC. J Hepatol 62, 977\u2013979.","DOI":"10.1016\/j.jhep.2014.10.046"},{"key":"BFsrep34252_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1749-6632.2009.03704.x","volume":"1155","author":"C Berasain","year":"2009","unstructured":"Berasain, C. et al. Inflammation and liver cancer. Ann. N. Y. Acad. Sci. 1155, 206\u2013221, (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFsrep34252_CR48","first-page":"31","volume":"1603","author":"NT Le","year":"2002","unstructured":"Le, N. T. & Richardson, D. R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. BBA-Rev. Cancer 1603, 31\u201346, (2002).","journal-title":"BBA-Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep34252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34252","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:09:52Z","timestamp":1672898992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep34252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,31]]}},"alternative-id":["BFsrep34252"],"URL":"https:\/\/doi.org\/10.1038\/srep34252","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"assertion":[{"value":"14 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34252"}}